How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

30,700 results for

Stimulant Use Disorder

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders

Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders Stimulant medication for ADHD not associated with subsequent substance use disorders | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stimulant medication for ADHD not associated with subsequent substance use disorders Article Text Aetiology Systematic review with meta-analysis Stimulant medication for ADHD

2014 Evidence-Based Medicine (Requires free registration)

22. Early initiation of amphetamine-type stimulants (ATS) use associated with lowered cognitive performance among individuals with co-occurring opioid and ATS use disorders in Malaysia. (PubMed)

Early initiation of amphetamine-type stimulants (ATS) use associated with lowered cognitive performance among individuals with co-occurring opioid and ATS use disorders in Malaysia. Amphetamine-type stimulants (ATS) use is increasingly prevalent in Malaysia, including among individuals who also use opioids. We evaluated cognitive functioning profiles among individuals with co-occurring opioid and ATS dependence and their lifetime patterns of drug use. Participants (N = 50) enrolling (...) of the developing brain to stimulant and/or neurotoxic effects of these drugs, the current study findings cannot preclude lowered cognitive performance before initiation of ATS use.

Full Text available with Trip Pro

2017 Journal of psychoactive drugs

23. Impact of Central Nervous System Stimulant Medication Use on Growth in Pediatric Populations with Attention-Deficit/Hyperactivity Disorder: A Review. (PubMed)

Impact of Central Nervous System Stimulant Medication Use on Growth in Pediatric Populations with Attention-Deficit/Hyperactivity Disorder: A Review. Central nervous system stimulants are a commonly used first-line treatment option for attention-deficit/hyperactivity disorder (ADHD). Stimulants are generally well tolerated, with anorexia and insomnia the most common adverse effects. However, there are some concerns with long-term use of stimulants, such as potential growth delay. Historically (...) , data regarding this long-term adverse effect have been conflicting. In this article, we review the newer data surrounding the effects of central nervous system stimulants on growth parameters in children with ADHD. We conducted a literature search of the PubMed database; only articles using ADHD criteria from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; and Diagnostic and Statistical

2018 Pharmacotherapy

24. Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder

Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Transcranial Magnetic Stimulation for Treatment of Methamphetamine Use Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03736317 Recruitment Status : Not yet recruiting First Posted : November 9, 2018 Last Update Posted

2018 Clinical Trials

25. A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD).

A Meta-Analysis of the Effectiveness of Different Cortical Targets Used in Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Obsessive-Compulsive Disorder (OCD). Randomised and sham-controlled trials (RCTs) of repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) have yielded conflicting results, which may be due to the variability in rTMS parameters used. We performed an updated systematic review and meta-analysis (...) on the effectiveness of rTMS for the treatment of OCD and aimed to determine whether certain rTMS parameters, such as cortical target, may be associated with higher treatment effectiveness. After conducting a systematic literature review for RCTs on rTMS for OCD through to 1 December 2016 using MEDLINE, PubMed, Web of Science, PsycINFO, Google, and Google Scholar, we performed a random-effects meta-analysis with the outcome measure as pre-post changes in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores

2018 The Psychiatric quarterly

26. Nucleus Accumbens Deep Brain Stimulation in Patients with Substance Use Disorders and Delay Discounting (PubMed)

Nucleus Accumbens Deep Brain Stimulation in Patients with Substance Use Disorders and Delay Discounting Deep brain stimulation (DBS) of the nucleus accumbens (NAc) shows first promising results in patients with severe substance use disorder (SUD), a patient group known to have deficits in self-control. One facet of self-control is the ability to forego smaller sooner rewards in favor of larger later rewards (delay discounting, DD). The NAc has been suggested to integrate motivational

Full Text available with Trip Pro

2018 Brain sciences

27. A Systematic Review of Attention Biases in Opioid, Cannabis, Stimulant Use Disorders (PubMed)

A Systematic Review of Attention Biases in Opioid, Cannabis, Stimulant Use Disorders Background: Opiates, cannabis, and amphetamines are highly abused, and use of these substances are prevalent disorders. Psychological interventions are crucial given that they help individuals maintain abstinence following a lapse or relapse into substance use. Advances in experimental psychology have suggested that automatic attention biases might be responsible for relapse. Prior reviews have provided (...) evidence for the presence of these biases in addictive disorders and the effectiveness of bias modification. However, the prior studies are limited, as they failed to include trials involving participants with these prevalent addictive disorders or have failed to adopt a systematic approach in evidence synthesis. Objectives: The primary aim of this current systematic review is to synthesise the current evidence for attention biases amongst opioid use, cannabis use, and stimulant use disorders

Full Text available with Trip Pro

2018 International journal of environmental research and public health

28. Investigating the Efficacy of Caloric Vestibular Stimulation in the Treatment of Substance Use Disorders

Investigating the Efficacy of Caloric Vestibular Stimulation in the Treatment of Substance Use Disorders Investigating the Efficacy of Caloric Vestibular Stimulation in the Treatment of Substance Use Disorders - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Investigating the Efficacy of Caloric Vestibular Stimulation in the Treatment of Substance Use Disorders The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03652311

2018 Clinical Trials

29. Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial

Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Deep Brain Stimulation (DBS) for the Treatment of Refractory Alcohol Use Disorder (AUD): Pilot Trial The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03660124 Recruitment

2018 Clinical Trials

30. Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder

Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Repetitive (...) Transcranial Magnetic Stimulation for Opiate Use Disorder (ArTMS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03538444 Recruitment Status : Recruiting First Posted : May 28, 2018 Last Update Posted : October 11, 2018 See

2018 Clinical Trials

31. Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder

Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Add-on Low Dose Dextromethorphan and Memantine in Patients With Amphetamine-type Stimulants Use Disorder The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03729128

2018 Clinical Trials

32. A Review of Brain Stimulation Methods to Treat Substance Use Disorders (PubMed)

A Review of Brain Stimulation Methods to Treat Substance Use Disorders Substance use disorders (SUDs) are a leading cause of disability worldwide. While several pharmacological and behavioral treatments for SUDs are available, these may not be effective for all patients. Recent studies using non-invasive neuromodulation techniques including Repetitive Transcranial Magnetic Stimulation (rTMS), Transcranial Direct Current Stimulation (tDCS), and Deep Brain Stimulation (DBS) have shown promise (...) similar results. Results are most encouraging when stimulation is targeted to the Dorsolateral Prefrontal Cortex (DLPFC).Short-term treatment with rTMS and tDCS may have beneficial effects on drug craving and consumption. Future studies should focus on extending therapeutic benefits by increasing stimulation frequency and duration of treatment.The utility of these methods in SUD treatment and prevention are unclear, and warrants further study using randomized, controlled designs. (Am J Addict 2018;27

Full Text available with Trip Pro

2018 The American Journal on Addictions

33. Longitudinal Trends in the Diagnosis of Attention-Deficit/Hyperactivity Disorder and Stimulant Use in Preschool Children on Medicaid. (PubMed)

Longitudinal Trends in the Diagnosis of Attention-Deficit/Hyperactivity Disorder and Stimulant Use in Preschool Children on Medicaid. To describe trends in the diagnosis of attention-deficit/hyperactivity disorder (ADHD) and prescribing of stimulants in preschool-age children receiving Medicaid and to identify factors associated with the receipt of psychosocial care.Data were extracted from 2012-2016 Kentucky Medicaid claims for children aged <6 years. ADHD was identified using International (...) the diagnosis but not receiving a stimulant, having at least 1 prescription written by a psychiatrist, having comorbidities, and age. The use of stimulants in children aged <6 years declined from 0.9% in 2012 to 0.5% in 2016.Promising trends demonstrate a decreasing use of stimulants in preschoolers; however, continued vigilance is needed to promote the optimal use of psychosocial interventions.Copyright © 2018 Elsevier Inc. All rights reserved.

2018 Journal of Pediatrics

34. Efficacy and safety of repetitive transcranial magnetic stimulation using an H1-coil or figure-8-coil in the treatment of unipolar major depressive disorder: A study protocol for a randomized controlled trial. (PubMed)

Efficacy and safety of repetitive transcranial magnetic stimulation using an H1-coil or figure-8-coil in the treatment of unipolar major depressive disorder: A study protocol for a randomized controlled trial. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive technique with few side effects that has been reported to be effective in the treatment of major depressive disorder (MDD). At present, no randomized controlled trials (RCT) have compared the efficacy and safety of rTMS (...) delivered by the figure-8-coil and the H1-coil. We describe an industry-independent, randomized, controlled, single-blinded, single-center study protocol assessing the differences in efficacy and safety of rTMS for patients diagnosed with MDD with the H1-coil and figure-8-coil as an add-on to stable pharmacotherapy or pharmacotherapy alone. Stimulation protocols follow those that led to the FDA clearance of these treatments for MDD. The sample of 76 patents in each of the three groups will be enrolled

Full Text available with Trip Pro

2018 Psychiatria Danubina Controlled trial quality: uncertain

35. High frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex for methamphetamine use disorders: A randomised clinical trial. (PubMed)

High frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex for methamphetamine use disorders: A randomised clinical trial. Repetitive transcranial magnetic stimulation (rTMS) is a brain stimulation and modulation electrophysiological technique, it can change cortical excitability of target brain region, modulate neuron plasticity and brain connections. Previous researches indicated that rTMS could reduce cue-induced craving in drug addiction.In (...) after 5 sessions of rTMS as compared to sham stimulation. Furthermore, real rTMS improved verbal learning and memory and social cognition in MA-addicted patients.The present study suggests that 10Hz rTMS of the left DLPFC may reduce craving and have no negative effects on cognitive function in MA-addicted patients, supporting the safety of rTMS in treating MA addiction.Copyright © 2017 Elsevier B.V. All rights reserved.

2018 Drug and alcohol dependence Controlled trial quality: uncertain

36. Amfetamine use disorder

Amfetamine use disorder Amfetamine use disorder - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Amfetamine use disorder Last reviewed: February 2019 Last updated: November 2018 Summary Amfetamines have certain therapeutic uses, but misuse potential is high. No medication has proven effective in breaking the misuse cycle. Aggressive psychological and sociological interventions are needed to reduce the high recidivism (...) rate. Definition Amfetamine use disorder involves the recreational use (other than for an approved medical indication) of a class of non-catecholamine sympathomimetic amines - specifically, amfetamines, metamfetamines, and 3,4-methylenedioxymethamfetamine (MDMA, also known as ecstasy), misused by oral and intravenous routes, nasal insufflation (snorting) and inhalation (smoking), resulting in either acute or chronic toxicity. Although these compounds have been used to improve alertness, enhance

2018 BMJ Best Practice

37. Amfetamine use disorder

Amfetamine use disorder Amfetamine use disorder - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Amfetamine use disorder Last reviewed: February 2019 Last updated: November 2018 Summary Amfetamines have certain therapeutic uses, but misuse potential is high. No medication has proven effective in breaking the misuse cycle. Aggressive psychological and sociological interventions are needed to reduce the high recidivism (...) rate. Definition Amfetamine use disorder involves the recreational use (other than for an approved medical indication) of a class of non-catecholamine sympathomimetic amines - specifically, amfetamines, metamfetamines, and 3,4-methylenedioxymethamfetamine (MDMA, also known as ecstasy), misused by oral and intravenous routes, nasal insufflation (snorting) and inhalation (smoking), resulting in either acute or chronic toxicity. Although these compounds have been used to improve alertness, enhance

2018 BMJ Best Practice

38. Opioid use disorder

substance use disorders, should be assessed. Physicians should be aware of methods for screening and detection of opioid use in clinical settings. Evidence-based treatments include detoxification, maintenance therapy, and psychosocial and supportive therapies. Treatment requires a multidisciplinary approach, is long term, and involves modifying deeply ingrained behaviours through the use of medications and psychosocial treatments. Definition An opioid is a synthetic or natural agent that stimulates (...) Opioid use disorder Opioid use disorder - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Opioid use disorder Last reviewed: February 2019 Last updated: January 2019 Summary Heroin and prescription opioid misuse is a major health concern. From a diagnostic perspective, it is imperative that the physician understands the criteria for opioid use disorder. Comorbid medical and psychiatric illnesses, as well as other

2018 BMJ Best Practice

39. Overview of substance use disorders and overdose

Overview of substance use disorders and overdose Overview of substance use disorders and overdose - Summary of relevant conditions | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Overview of substance use disorders and overdose Last reviewed: February 2019 Last updated: November 2018 Introduction According to the United Nations Office on Drugs and Crime (UNODC), it is estimated that 1 in 20 adults, or a quarter of a billion people between the ages (...) , both occasionally and regularly, tend to be polydrug users who use more than one substance concurrently or sequentially. United Nations Office on Drugs and Crime. World drug report 2016. May 2016 [internet publication]. https://www.unodc.org/doc/wdr2016/WORLD_DRUG_REPORT_2016_web.pdf Related conditions Condition Description An opioid is a synthetic or natural agent that stimulates opioid receptors and produces opium-like effects. Opiates are opioids that are naturally derived from the opium poppy

2018 BMJ Best Practice

40. Overview of substance use disorders and overdose

Overview of substance use disorders and overdose Overview of substance use disorders and overdose - Summary of relevant conditions | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Overview of substance use disorders and overdose Last reviewed: February 2019 Last updated: November 2018 Introduction According to the United Nations Office on Drugs and Crime (UNODC), it is estimated that 1 in 20 adults, or a quarter of a billion people between the ages (...) , both occasionally and regularly, tend to be polydrug users who use more than one substance concurrently or sequentially. United Nations Office on Drugs and Crime. World drug report 2016. May 2016 [internet publication]. https://www.unodc.org/doc/wdr2016/WORLD_DRUG_REPORT_2016_web.pdf Related conditions Condition Description An opioid is a synthetic or natural agent that stimulates opioid receptors and produces opium-like effects. Opiates are opioids that are naturally derived from the opium poppy

2018 BMJ Best Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>